Hua Medicine: Revenue up 74% and gross margin improved, with net loss narrowing amid strong sales growth
I'm LongbridgeAI, I can summarize articles.Revenue surged 74% year-over-year to RMB378.9 million, driven by HuaTangNing’s rapid sales growth and improved gross margin. Net loss narrowed to RMB30.2 million, with strong cash reserves supporting ongoing R&D and expansion. Robust pipeline and regional expansion underpin positive outlook.Original document: Hua Medicine Ltd. [2552] Earnings Release — Aug. 21 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Revenue surged 74% year-over-year to RMB378.9 million, driven by HuaTangNing’s rapid sales growth and improved gross margin. Net loss narrowed to RMB30.2 million, with strong cash reserves supporting ongoing R&D and expansion. Robust pipeline and regional expansion underpin positive outlook.
Original document: Hua Medicine Ltd. [2552] Earnings Release — Aug. 21 2026